



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BIOMARK ANNOUNCES PATENT GRANTED IN CHINA

Vancouver, British Columbia – (October 25th, 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “A METHOD FOR ASSAYING THE ACTIVITY OF SPERMIDINE/SPERMINE N1-ACETYLTRANSFERASE” has been prosecuted to allowance and issued in China.

Rashid Ahmed, President and CEO, says, “Granting of this patent expands and strengthens our portfolio beyond a single compound thus allowing the company additional freedom to select potentially better signaling candidates. Issuance of the patent in China is important as we accelerate our development in commercializing our technology platform for this prime diagnostic market. In addition, BioMark is now well positioned as far as expiration of its initial patent is concerned”.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

For further information on BioMark, please Contact:

Rashid Ahmed Bux
President & CEO

BioMark Diagnostics Inc.

Tel. 604-282-6567

Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press

release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.